On June 27, 2014, Retrophin, Inc. (NASDAQ: RTRX) provided preliminary single patient data from the first Pantothenate kinase-associated neurodegeneration (“PKAN”) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE